Revised EMA guideline on first-in-human and early phase studies [Regulatives / Guidelines]

posted by Ohlbe – France, 2017-07-25 20:52 (3260 d 08:15 ago) – Posting: # 17614
Views: 2,672

Dear all,

I know this is a bit far from bioequivalence trials, but we had some discussions on FIM here after the Bial trial accident.

The EMA has published today its revised guideline on strategies to identify and mitigate risks for first-in-human and early clinical trials with investigational medicinal products.

According to the associated press release, the overview of comments will be published in September.
—
Regards
Ohlbe

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,570 registered users;
345 visitors (0 registered, 345 guests [including 21 identified bots]).
Forum time: 05:07 CEST (Europe/Vienna)

Most scientists today are devoid of ideas, full of fear, intent on
producing some paltry result so that they can add to the flood
of inane papers that now constitutes “scientific progress”
in many areas.    Paul Feyerabend

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5